Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure

Apabetalone development program moving toward next study to enable a New Drug Application filing

CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes,” in the high-impact, peer-reviewed Journal of the American Medical Association (JAMA).

The publication can be viewed using the following LINK.

“The results published in JAMA bode well for the future development of apabetalone,” said Professor Kausik Ray, Professor of Public Heath, Imperial College London, and the lead author of the study. “We have learned a great deal from the data generated in BETonMACE, which is being applied to the design of Resverlogix’s next study to address an unmet need in a high-risk patient population.”

As commented by Dr. Jorge Plutzky, MD, Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, in a JAMA Editorial published March, 27, 2020, titled: “Epigenetic Therapeutics for Cardiovascular Disease Writing, Erasing, Reading, and Maybe Forgetting,” Dr. Plutzky stated, “Exploratory analysis of secondary end points […] suggested that apabetalone was associated with a reduced risk of first (29 vs 48, P=.03) or first and recurrent congestive heart failure (CHF) hospitalizations (35 vs 70).” Dr. Plutzky further commented that ‘the possible effects of apabetalone on heart failure outcomes suggests an expanded CHF end point might have reached significance’. The full online editorial can be accessed HERE.  

“We are very encouraged by the results presented in JAMA and the accompanying editorial – which is based on the large Phase 3 trial, BETonMACE – the first ever testing a BET inhibitor for a cardiovascular disease indication,” said Dr. Michael Sweeney, Senior Vice President, Clinical Development of Resverlogix. “The addition of apabetalone to standard of care therapy in the trial’s high-risk patient population showed a strong trend towards a reduction in major adverse cardiac events (MACE) and hospitalization for heart failure. Apabetalone’s strong safety profile, along with the latest published results, allows us to move this novel therapy into a subsequent study under US FDA granted Breakthrough Therapy Designation to enable a New Drug Application filing.”